With the recent success of Wegovy and Mournjaro, coupled with the ongoing surge in M&A activity and substantial reinvestment in expanding manufacturing sites, the momentum in obesity drug development remains relentless.

Covering everything from target validation and proof of concept to clinical outcomes and market opportunity, the 2nd Obesity & Weight Loss Drug Development Summit was the only conference with a focused perspective on industry decisions and solutions essential for delivering more tolerable and sustainable oral or injectable weight loss therapies. 

From GLP-1RAs to triple GIP, GLP-1, and glucagon receptor agonists, with a focus on targeting mechanisms outside of appetite suppression, preserving lean muscle mass, and future combination rationale, this summit brought together 80+ experts in obesity and weight loss from biotech, pharma and venture capital. Together, they accelerated the development of the next generation of longer-lasting weight loss drugs.